Search alternatives:
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
linear decrease » linear increase (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
linear decrease » linear increase (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
7041
Comparison of demographic features.
Published 2025“…Additionally, a decrease in birth weight was significantly linked to an increased risk of readmission (OR = 0.998, P = 0.013), although the effect size was relatively small.…”
-
7042
Data.
Published 2025“…Additionally, a decrease in birth weight was significantly linked to an increased risk of readmission (OR = 0.998, P = 0.013), although the effect size was relatively small.…”
-
7043
Comparison of examination test and treatment.
Published 2025“…Additionally, a decrease in birth weight was significantly linked to an increased risk of readmission (OR = 0.998, P = 0.013), although the effect size was relatively small.…”
-
7044
Specifications of prototypes of RSSCA system.
Published 2025“…Compared to conventional PV systems, the RSSCA offers improved light uniformity, better land-use efficiency, and significantly higher electricity generation. However, in regions with limited direct sunlight, such as Seoul in winter, system performance decreases. …”
-
7045
Software testing process flowchart.
Published 2025“…Results demonstrate that the developed appraoch is highly accurate and significantly faster than manual classification, which can dramatically decrease software development time and cost.…”
-
7046
The ROC of LR for three classes.
Published 2025“…Results demonstrate that the developed appraoch is highly accurate and significantly faster than manual classification, which can dramatically decrease software development time and cost.…”
-
7047
The ROC of MNB for three classes.
Published 2025“…Results demonstrate that the developed appraoch is highly accurate and significantly faster than manual classification, which can dramatically decrease software development time and cost.…”
-
7048
Problem solution process model.
Published 2025“…Results demonstrate that the developed appraoch is highly accurate and significantly faster than manual classification, which can dramatically decrease software development time and cost.…”
-
7049
The ROC of SVM for three classes.
Published 2025“…Results demonstrate that the developed appraoch is highly accurate and significantly faster than manual classification, which can dramatically decrease software development time and cost.…”
-
7050
The ROC of RF for three classes.
Published 2025“…Results demonstrate that the developed appraoch is highly accurate and significantly faster than manual classification, which can dramatically decrease software development time and cost.…”
-
7051
The ROC of GNB for three classes.
Published 2025“…Results demonstrate that the developed appraoch is highly accurate and significantly faster than manual classification, which can dramatically decrease software development time and cost.…”
-
7052
The accuracy of classifiers and voting plans.
Published 2025“…Results demonstrate that the developed appraoch is highly accurate and significantly faster than manual classification, which can dramatically decrease software development time and cost.…”
-
7053
Metrics formula [24].
Published 2025“…Results demonstrate that the developed appraoch is highly accurate and significantly faster than manual classification, which can dramatically decrease software development time and cost.…”
-
7054
-
7055
Baseline characteristics of participants.
Published 2025“…In the multivariable Cox regression analysis, eGFR > 120 mL/min ∙ 1.73 m<sup>2</sup> was associated with a decreased risk of dyslipidemia (HR: 0.35; 95% CI [0.34–0.36]). …”
-
7056
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
Published 2025“…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”
-
7057
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
Published 2025“…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”
-
7058
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
Published 2025“…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”
-
7059
Supplementary file 1_Ivarmacitinib reduces the need for adding/escalating medications in moderate-to-severe rheumatoid arthritis patients: a post hoc analysis from a phase III tria...
Published 2025“…</p>Conclusion<p>Ivarmacitinib significantly reduces the need for adding/escalating medications compared to placebo, thereby potentially decreasing treatment burden. …”
-
7060